Immunogenicity of 9-valent HPV Vaccine

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 7, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

March 1, 2025

Conditions
Human Papilloma Virus Infection
Interventions
BIOLOGICAL

9-valent HPV vaccine

All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.

Trial Locations (1)

28046

RECRUITING

Hospital Universitario La paz, Madrid

All Listed Sponsors
lead

Talia Sainz Costa

OTHER